Biofrontera Inc. (BFRI) vs Lisata Therapeutics, Inc. (LSTA)
A side-by-side comparison of Biofrontera Inc. and Lisata Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BFRI
Biofrontera Inc.
$0.92HealthcareDelayed quote: Oct 6, 2026, 11:30 AM EDT
LSTA
Lisata Therapeutics, Inc.
$1.21HealthcareDelayed quote: Oct 6, 2026, 11:30 AM EDT
Total return — BFRI vs LSTA
growth of $100 · dividends reinvested · last 5yBFRI -99.0% (-60.1%/yr)LSTA -92.4% (-40.3%/yr)LSTA compounded faster over this window
Log scale — wide-divergence pair
BFRI LSTA
BFRI vs LSTA: by the numbers
- •BFRI is the larger company ($12M vs $11M market cap).
- •Both run net losses; BFRI's is the smaller (-13.78% vs -14621.00% net margin).
Metrics side by side
Valuation
| Metric | BFRI | LSTA |
|---|---|---|
| P/S ratio | 0.26 | 110.19 |
| P/B ratio | 1.98 | 1.34 |
Profitability
| Metric | BFRI | LSTA |
|---|---|---|
| Gross margin | 84.45% | 14.12% |
| Operating margin | -21.94% | -10711.18% |
| Net margin | -13.78% | -14621.00% |
| ROE | -106.87% | -177.35% |
| ROIC | -32.27% | -204.32% |
Growth (annualized)
| Metric | BFRI | LSTA |
|---|---|---|
| Revenue CAGR (5Y) | 15.55% | N/A |
| Total return CAGR (5Y) | N/A | -40.75% |
Go deeper
Dig into the metrics
Biofrontera ROELisata Therapeutics ROEBiofrontera operating marginLisata Therapeutics operating marginBiofrontera revenue growthLisata Therapeutics revenue growthBiofrontera free cash flowLisata Therapeutics free cash flow
Biofrontera & Lisata Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.